Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Bearish flow noted in Bristol Myers (BMY) Squibb with 6,501 puts trading, or 1.1x expected. Most active are Nov-24 59 puts and 11/29 weekly 50 puts, with total volume in those strikes near 3,400 ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of ...

With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood ...

Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia ...

Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...